The Myeloma Trial Finder lists the clinical trials that are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.

Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone, please call the Myeloma Infoline on 0800 980 3332

Last update: 02/05/2024

There are currently 38 open trials. In 141 locations

What is a Clinical Trial?

Step 2: Choose a Trial

There are currently 38 open trials

Step 3: View Details

Trial Title:

PET scans for diagnosing cardiac AL amyloidosis (CArdiag)

Treatments:

Myeloma stage:

AL amyloidosis

Trial phase:

III

Summary

Summary:

This trial is investigating how effective Positron Emission Tomography (PET) scans using a diagnostic radiotracer called [18F]florbetaben is in diagnosing cardiac AL amyloidosis, compared to standard diagnostic procedures.

This trial is exploring diagnostic tests only. It is not a new treatment for AL Amyloiosis. Patients will still recieve usual Standard of Care (SoC).

Locations

Locations:

Royal Free Hospital, London

Who can enter the study?

Who can enter the study?:

Patients with suspected cardiac (affecting the heart) AL amyloidosis.

What's involved?

What's involved?:

Patients will recieve a diagnostic radiotracer called [18F]florbetabensubjected and will then have a Positron Emission Tomography (PET) scan.
Clinical Information

Clinical Information
(for Medical Professionals):

This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with suspected cardiac amyloidosis or with a putative diagnosis of cardiac amyloidosis but with remaining diagnostic uncertainty (e.g., unclear etiology or cardiac manifestation) or patients with diagnosis of amyloidosis but unclear cardiac involvement.

The diagnostic efficacy of the visual and quantitative assessments of [18F]florbetaben PET images for diagnosis of cardiac AL Amyloidosis will be determined by comparison to the standard of truth (SoT) obtained through standard of care clinical diagnosis.

For more information, click here.

Find

Find out more about Myeloma UK:

Visit www.myeloma.org.uk

Do you want to talk to someone? Call our myeloma Infoline